HEALEY ALS Platform Trial – Regimen I NUZ-001 Purpose of the study? The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen I will evaluate the safety and efficacy of a single study drug, NUZ-001, in participants with ALS. Link […]
HEALEY ALS Platform Trial – Regimen I NUZ-001 Read More »
CorEvitas Myasthenia Gravis Registry Purpose of the study? The design is a prospective, observational (non-interventional) registry for subjects with myasthenia gravis under the care of a neurology provider. Longitudinal data are collected from both subjects and their treating neurology provider during routine clinical encounters using a structured and standardized data collection method. Link to clinicaltrials.gov
CorEvitas Myasthenia Gravis Registry Read More »
UCB Ocular Myasthenia Gravis Purpose of the study? The purpose of the study is to demonstrate the efficacy, safety and tolerability of rozanolixizumab compared with placebo in the treatment of adult study participants with Ocular Myasthenia Gravis. Notable Inclusion Criteria: Weakness in muscles of the eye but normal strength in all other facial, bulbar, and
UCB Ocular Myasthenia Gravis Read More »
REVITALYZ: Safety and Efficacy of FT218 in Idiopathic Hypersomnia About the study? This is a double-blind, placebo-controlled study of the efficacy and safety of FT218. FT218 drug product is a once-nightly formulation of sodium oxybate for extended-release oral suspension. The study will enroll subjects who are diagnosed with idiopathic hypersomnia. Subjects will be eligible to
REVITALYZ: Safety and Efficacy of FT218 in Idiopathic Hypersomnia Read More »
Praxis RADIANT/POWER-1/Open-label Extension About the study? The Praxis studies are investigating how well vormatrigine works for treating focal onset seizures compared with placebo, as well as its safety and side effects compared with placebo. Vormatrigine is a new investigational medicine that is taken once a day and is currently being studied to see if it
Praxis RADIANT/POWER-1/Open-label Extension Read More »
Xenon X-TOLE2/X-ACT/X-TOLE4 (Active, No longer Recruiting) About the study? About Study: The Xenon studies are investigating the effect of a novel anti-seizure medication, XEN1101, on seizure frequency for patients diagnosed with Focal or Generalized Epilepsy. Patients will take either the active study drug or the placebo, and have the option to enroll in a long-term
Xenon X-TOLE2/X-ACT/X-TOLE4 Read More »
Seratrials: Biological Samples Collection Purpose of the study? SeraTrials is a biotechnology company that partners with major pharmaceutical, biotechnology and diagnostic companies for the development of diagnostic assays and biologicals drug development. SeraTrials requires control blood samples from donors, not currently involved in dosing studies. These blood samples are essential for researchers to further their
RxFunction: Balance4Mobility: Walkasin’s Device About the study? Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems. Purpose of the study? The goal of this clinical trial is to is to test whether Walkasins can help people with peripheral neuropathy maintain their balance better. The main question it aims to answer is
RxFunction Balance4Mobility: Walkasin’s Device Read More »
Biohaven BHV7000 Rise Focal Epilepsy Study About the study? A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety, and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy. Purpose of the study? If you or a loved one have been diagnosed with focal onset epilepsy, are between the ages of
Biohaven BHV7000 Rise Read More »
Praxis Power2 study for Focal Epilepsy About the study? A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures. Purpose of the study? The main purpose of this research is to see how well vormatrigine works for treating focal onset seizures compared with placebo, as well as its
Praxis Power2 study Read More »
